The exponential rise in patients presenting with obesity and type 2 diabetes has resulted in an increased interest from pharmaceutical companies for the use of PTP1B inhibitors as potential therapeutics [20]. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.